Abstract
The cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) gene has been implicated in the regulation of blood pressure (BP) and thus, may serve as a potential risk factor for the development of hypertension. However, current results regarding the association between CYP3A5 single nucleotide polymorphisms and BP/hypertension have been inconsistent. In this study, we performed a meta-analysis to evaluate the association between the CYP3A5 rs776746 (6986G>A) polymorphism and BP/hypertension. Ten studies (representing 2799 cases and 6794 controls) were included to determine the association of this single nucleotide polymorphism with hypertension, and 12 studies (9076 subjects) were included to determine the association of this single nucleotide polymorphism with BP. Overall, no associations were observed between the rs776746 polymorphism and BP/hypertension. In subgroup analysis, CYP3A5*1 carriers had lower systolic BP, compared with non-carriers in white populations (mean difference=−1.322, 95% confidence interval −2.401 to −0.242 mm Hg, P=0.016). This meta-analysis suggested a modestly significant association between the CYP3A5 rs776746 polymorphism and systolic BP in white populations. Given the limited sample size, additional studies are necessary to investigate the role of CYP3A5 in the regulation of BP and the pathogenesis of hypertension.
Similar content being viewed by others
Introduction
Hypertension affects nearly one-third of the adult population worldwide and is associated with stroke and cardiovascular disease, which are major contributors to the global health burden.1 Although lifestyle factors (for example, excess sodium intake and lack of physical activity) can contribute to elevated blood pressure (BP) and increased hypertension risks,2 genetic factors have also been implicated in the pathogenesis of these diseases.3, 4, 5 Genome-wide association studies have identified many genetic variants that may be associated with hypertension.6 These exciting new results elucidating hypertension's underlying molecular mechanisms have greatly expanded our knowledge and provided new insights into the etiology of hypertension.7
The cytochrome P450 family 3 subfamily A polypeptide 5 (CYP3A5) gene encodes a member of the cytochrome P450 super family of enzymes. The CYP3A5 gene is part of a cluster of cytochrome P450 genes on chromosome 7q21.1.8 Cytochrome P450 proteins are monooxygenases that have an important role in the metabolism of both endogenous substances (for example, hormones) and exogenous substances (for example, drugs).9, 10 Cytochrome P450 proteins are expressed in an organ-specific manner, with CYP3A5 predominantly expressed in the kidney.11 As a glucocorticoid 6β-hydroxylase, the CYP3A5 enzyme converts cortisol or corticosterone to 6β-corticosterone, which may lead to increased sodium and water retention.12, 13 The CYP3A5 gene has a common polymorphism (6986G>A, rs776746) in the third intron. The G allele generates an aberrant RNA splicing site and results in a premature stop codon, which causes truncation of the CYP3A5 protein.14 In genetic epidemiology studies, CYP3A5*1 refers to the A allele (functional allele) and CYP3A5*3 refers to the G allele (nonfunctional allele).
Recently, several studies have suggested a possible relationship between CYP3A5 gene polymorphisms and BP/hypertension. However, their conclusions have been inconsistent. This inconsistency could be due to many factors, including insufficient statistical power, varying recruitment procedures of the study population and differences in the genetic and environmental backgrounds. In this study, we performed a meta-analysis to assess the association between the CYP3A5 rs776746 polymorphism and BP/hypertension.
Methods
Literature and search strategy
We searched literature databases, including PubMed (1950 to 2010), the ISI Web of Science (1975 to 2010) and Embase (1966 to 2010). The search strategy to identify all possible studies involved the use of the following key words: ‘cytochrome P-450 3A5’ (or ‘CYP3A5’) and ‘blood pressure’ (or ‘hypertension’). The reference lists of retrieved articles were then manually searched. If more than one article was published using the same case series, only the study with largest sample size was included. The literature search was updated on 5 December 2010.
Inclusion criteria and data extraction
The studies included in the meta-analysis necessarily met all of the following inclusion criteria: (1) evaluating the association of the CYP3A5 polymorphism with hypertension or BP; (2) a case–control design; (3) sufficient data for calculation of effect size (odds ratio (OR) or mean difference) with a corresponding confidence interval (CI); and (4) subjects without serious diseases. The following information was extracted from each study: (1) the name of the first author; (2) the year of publication; (3) the ethnicity of the study population; (4) the gender ratio and mean age (or age range) of the study population; (5) the number of subjects with the CYP3A5 polymorphism in hypertension cases and controls; and (6) the mean and s.d. of BP among carriers and non-carriers with CYP3A5*1. The articles were independently assessed for compliance with the inclusion/exclusion criteria, and all disagreements were resolved to give a consistent decision for each article.
Statistical analysis
The association of the CYP3A5 polymorphism with hypertension was estimated by calculating the pooled OR and the 95% CI. The association with BP was estimated by calculating the pooled mean differences and the 95% CI. The significance of the pooled effect size was determined by a Z-test (P<0.05 was considered statistically significant). A Q-test was performed to evaluate whether the variation was due to heterogeneity or by chance. A random (DerSimonian–Laird method15)- or fixed (Mantel–Haenszel method16)-effects model was used to calculate the pooled effect estimates in the presence (P<=0.10) or absence (p>0.10) of heterogeneity, respectively. Begg's funnel plot, a scatter plot of effect against a measure of study size, was generated as a visual aid to detect bias or systematic heterogeneity.17 Publication bias was assessed by Egger's test18(P<0.05 was considered statistically significant). Subgroup analysis by ethnicity was also performed. To evaluate the stability of the results, sensitivity analysis was performed by removing one study at a time. Data analysis was performed using STATA version 11 (StataCorp LP, College Station, TX, USA) as described previously.19, 20, 21, 22, 23
Results
Characteristics of the studies
The literature search identified a total of 52 potentially relevant papers. Of these, 35 were excluded because of obvious irrelevance ascertained by reading the titles and abstracts. Some studies were excluded, because the subjects were pregnant women,24 renal transplant patients,25 coronary angioplasty patients26 or coronary artery disease patients (INVEST-GENES cohort).27 The subjects of two papers28, 29 were from the same cohort; therefore, only one paper was included.29 One paper was excluded, because its study population contained only one CYP3A5*3/*3 allele carrier.30 Therefore, 12 papers met the inclusion criteria and were included in the meta-analysis.27, 29, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40 Individuals carrying at least one CYP3A5*1 allele were combined as CYP3A5*1 carriers in one group (high expression), and individuals without a CYP3A5*1 allele were combined as CYP3A5*1 non-carriers in the other group (low expression). The characteristics of the included studies are listed in Tables 1 and 2.
Meta-analysis for determining the association with hypertension
Ten sub-studies with 2799 cases and 6794 controls were included to determine the association with hypertension.27, 33, 34, 35, 38 Overall, there was evidence of heterogeneity between studies (P=0.064, I-squared=44.2%). Under a random-effects model, the meta-analysis result showed no association between the CYP3A5 rs776746 polymorphism and hypertension (OR=1.123, 95% CI 0.906 to 1.394, P=0.290). In the subgroup analysis of groups stratified by ethnicity, the heterogeneity was not significant in the white subgroup (p>0.10), but it remained in black populations (P<0.10). The subgroup meta-analysis results showed that there was no association between the CYP3A5 rs776746 polymorphism and hypertension in either white (OR=1.016, 95% CI 0.880 to 1.172, P=0.831) or black populations (OR=1.278, 95% CI 0.554 to 2.948, P=0.566; Figure 1 and Table 3). Sensitivity analysis was performed by excluding a single study at a time and similar results were obtained (data not shown).
Meta-analysis to determine the association with BP
Twelve sub-studies with 9076 subjects were included to determine the association with BP.27, 29, 31, 32, 35, 36, 37, 38, 39, 40 As shown in Figures 2 and 3, there was evidence of heterogeneity between studies (systolic BP (SBP): P=0.056, I-squared=43.0%; diastolic BP (DBP): P=0.029, I-squared=48.8%). Overall, the meta-analysis results showed no association between the CYP3A5 rs776746 polymorphism with either SBP or DBP (for SBP: mean difference=−0.242, 95% CI −1.576 to 1.093, P=0.722; for DBP: mean difference=−0.207, 95% CI −1.173 to 0.759, P=0.675). After stratification by ethnicity, the heterogeneity was not significant in white populations (P>0.10). The subgroup meta-analysis showed that, in white populations, CYP3A5*1 carriers had significantly lower SBP compared with non-carriers (mean difference=−1.322, 95% CI −2.401 to −0.242 mm Hg, P=0.016; Figure 4 and Table 3). The stability of these results was also confirmed by sensitivity analysis (data not shown).
Publication bias
Begg's funnel plots were generated to assess potential publication bias (figures not shown). No publication bias was detected (Egger's test, P=0.243, 0.179 and 0.516 for the associations with hypertension, SBP and DBP, respectively).
Discussion
In this study, we performed a meta-analysis to investigate the association between the CYP3A5 rs776746 polymorphism and BP/hypertension. Overall, no significant association was observed either for BP or hypertension. However, significant heterogeneity was found in the studies. In meta-analyses, it is well accepted that potential heterogeneity between studies may interfere with the conclusions. Given the large interethnic differences in allele frequencies,41 a subgroup analysis based on ethnicity was performed. Except for hypertension risks in blacks, heterogeneity was not significant within each ethnic group. We found a significant association between the CYP3A5 rs776746 polymorphism and SBP in whites. The sensitivity analysis results confirmed these conclusions.
Currently, data on the association of CYP3A5 polymorphisms with BP or hypertension are relatively limited. Givens et al.31 first reported that the CYP3A5*1 allele was associated with increased SBP, but not DBP in 25 African Americans. Since then, several studies have been performed to investigate the association in different ethnic populations; however, the results have been inconsistent. For example, a large population-based study (n=6777, age range: 28–75 years) by Kreutz et al.35 showed that the CYP3A5*1 allele was associated with lower SBP only in women. In a study of an elderly Finnish Caucasian population (n=373, age: ⩾75 years), CYP3A5*1 carriers had a significantly greater hypertension risk.34 In a Japanese population, the CYP3A5*1 allele was associated with DBP, but not SBP, and further analysis showed that the significant association was observed only among *3/*3 carriers with high salt intake. This indicated that the CYP3A5 rs776746 polymorphism might be a risk factor for salt sensitivity.40
The underlying biological mechanism by which CYP3A5 exerts its effects on the pathogenesis of hypertension is still not known. As a potential intermediate phenotype, cortisol may have an important role in the regulation of BP levels and the development of hypertension.42 Some previous studies suggest that excessive intrarenal conversion of cortisol to 6β-hydroxycoricosterone through increased renal CYP3A activity could enhance post-renal proximal tubular sodium reabsorption and thus result in elevated BP levels.12, 13 However, CYP3A could also protect the expression of corticosterone-induced active sodium transport in kidney cells by mineralocorticoid receptor-mediated mechanisms, which could then lead to decreased BP.43 This may be the underlying mechanism by which the CYP3A5*1 allele resulted in a lower SBP.
The current meta-analysis has advantages over individual studies; however, it does have some limitations. First, it was based primarily on unadjusted effect estimates and confidence intervals. Second, the methods for measuring BP were not uniform for the included studies (office BP vs. ambulatory BP monitoring). Third, there may also be an age effect, because in some populations, the CYP3A5 genotype was associated with a different profile of BP increases with age. Fourth, the effect of gene–gene and gene–environment interactions (salt intake is an example of the latter) was not addressed in this meta-analysis. Finally, if the various populations are considered separately, the results of the subgroup analysis should be interpreted with caution because of limited statistical power. We anticipate that these issues will be addressed in future studies.
In summary, our meta-analysis suggested a modestly significant association between the CYP3A5*1 genotype and a lower SBP in white populations. Given the strong interethnic differences in CYP3A5*1 allele frequency, it is possible that the effects of CYP3A5 may vary depending on the genetic context and physiological background. As the CYP3A5 gene has been implicated in BP regulation, additional epidemiological, biological and clinical studies are required to further investigate the role of CYP3A5 in the pathogenesis of hypertension.
References
Lawes CM, Vander Hoorn S, Rodgers A . Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513–1518.
Whelton PK, He J, Appel LJ, Cutler JA, Havas S, Kotchen TA, Roccella EJ, Stout R, Vallbona C, Winston MC, Karimbakas J . Primary prevention of hypertension: clinical and public health advisory from The National High Blood Pressure Education Program. JAMA 2002; 288: 1882–1888.
Binder A . A review of the genetics of essential hypertension. Curr Opin Cardiol 2007; 22: 176–184.
Franceschini N, Reiner AP, Heiss G . Recent findings in the genetics of blood pressure and hypertension traits. Am J Hypertens 2011; 24: 392–400.
Tanira MO, Al Balushi KA . Genetic variations related to hypertension: a review. J Hum Hypertens 2005; 19: 7–19.
Ehret GB . Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. Curr Hypertens Rep 2010; 12: 17–25.
Wang C . Genetic association studies: hypertension and beyond. Hypertension Res 2011; 34: 294–295.
Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, Deglmann CJ, Burk O, Buntefuss D, Escher S, Bishop C, Koebe HG, Brinkmann U, Klenk HP, Kleine K, Meyer UA, Wojnowski L . Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 2001; 11: 111–121.
Eichelbaum M, Burk O . CYP3A genetics in drug metabolism. Nat Med 2001; 7: 285–287.
Daly AK . Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet 2006; 45: 13–31.
Haehner BD, Gorski JC, Vandenbranden M, Wrighton SA, Janardan SK, Watkins PB, Hall SD . Bimodal distribution of renal cytochrome P450 3A activity in humans. Mol Pharmacol 1996; 50: 52–59.
Watlington CO, Kramer LB, Schuetz EG, Zilai J, Grogan WM, Guzelian P, Gizek F, Schoolwerth AC . Corticosterone 6 beta-hydroxylation correlates with blood pressure in spontaneously hypertensive rats. Am J Physiol 1992; 262: F927–F931.
Ghosh SS, Basu AK, Ghosh S, Hagley R, Kramer L, Schuetz J, Grogan WM, Guzelian P, Watlington CO . Renal and hepatic family 3A cytochromes P450 (CYP3A) in spontaneously hypertensive rats. Biochem Pharmacol 1995; 50: 49–54.
Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E . Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27: 383–391.
DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177–188.
Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719–748.
Begg CB, Mazumdar M . Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088–1101.
Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629–634.
Liu L, Zhuang W, Wang C, Chen Z, Wu XT, Zhou Y . Interleukin-8 -251 A/T gene polymorphism and gastric cancer susceptibility: a meta-analysis of epidemiological studies. Cytokine 2010; 50: 328–334.
Sun L, Xi B, Yu L, Gao XC, Shi DJ, Yan YK, Xu DJ, Han Q, Wang C . Association of glutathione S-transferases polymorphisms (GSTM1 and GSTT1) with senile cataract: a meta-analysis. Invest Ophthalmol Vis Sci 2010; 51: 6381–6386.
Wang R, Zhong B, Liu Y, Wang C . Association between alpha-adducin gene polymorphism (Gly460Trp) and genetic predisposition to salt sensitivity: a meta-analysis. J Appl Genet 2010; 51: 87–94.
Wang R, Zhou D, Xi B, Ge X, Zhu P, Wang B, Zhou M, Huang Y, Liu J, Yu Y, Wang C . ENPP1/PC-1 Gene K121Q polymorphism is associated with obesity in european adult populations: evidence from a meta-analysis involving 24 324 subjects. Biomed Environ Sci 2011; 24: 200–206.
Zhang S, Wang C, Xi B, Li X . Association between the tumour necrosis factor-alpha-308G/A polymorphism and chronic obstructive pulmonary disease: an update. Respirology 2011; 16: 107–115.
Coto E, Tavira B, Marin R, Ortega F, Lopez-Larrea C, Ruiz-Ortega M, Ortiz A, Diaz M, Corao AI, Alonso B, Alvarez V . Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy. Biochem Biophys Res Commun 2010; 397: 576–579.
Kreutz R, Zurcher H, Kain S, Martus P, Offermann G, Beige J . The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients. Pharmacogenetics 2004; 14: 665–671.
Suh JW, Koo BK, Zhang SY, Park KW, Cho JY, Jang IJ, Lee DS, Sohn DW, Lee MM, Kim HS . Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel. CMAJ 2006; 174: 1715–1722.
Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA . Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007; 81: 386–391.
Eap CB, Bochud M, Elston RC, Bovet P, Maillard MP, Nussberger J, Schild L, Shamlaye C, Burnier M . CYP3A5 and ABCB1 genes influence blood pressure and response to treatment, and their effect is modified by salt. Hypertension 2007; 49: 1007–1014.
Bochud M, Eap CB, Elston RC, Bovet P, Maillard M, Schild L, Shamlaye C, Burnier M . Association of CYP3A5 genotypes with blood pressure and renal function in African families. J Hypertens 2006; 24: 923–929.
Neville KA, Ayaji OE, Holland CL, Skaar TC, Hall SD . Association between CYP3A5 and blood pressure in nigerian males. Clin Pharmacol Ther 2005; 77: P55–P55 (doi:10.1016/j.clpt.2004.1012.1099).
Givens RC, Lin YS, Dowling AL, Thummel KE, Lamba JK, Schuetz EG, Stewart PW, Watkins PB . CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol 2003; 95: 1297–1300.
Fromm MF, Schmidt BM, Pahl A, Jacobi J, Schmieder RE . CYP3A5 genotype is associated with elevated blood pressure. Pharmacogenet Genomics 2005; 15: 737–741.
Ho H, Pinto A, Hall SD, Flockhart DA, Li L, Skaar TC, Cadman P, O′Connor DT, Wagner U, Fineberg NS, Weinberger MH . Association between the CYP3A5 genotype and blood pressure. Hypertension 2005; 45: 294–298.
Kivisto KT, Niemi M, Schaeffeler E, Pitkala K, Tilvis R, Fromm MF, Schwab M, Lang F, Eichelbaum M, Strandberg T . CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am J Pharmacogenomics 2005; 5: 191–195.
Kreutz R, Zuurman M, Kain S, Bolbrinker J, de Jong PE, Navis G . The role of the cytochrome P450 3A5 enzyme for blood pressure regulation in the general Caucasian population. Pharmacogenet Genomics 2005; 15: 831–837.
Marunde R, Jin Y, Ayaji O, Neville K, Phillips S, Skaar TC, Hall SD . CYP3A5 genotypes and blood pressure in healthy Nigerian males. Clin Pharmacol Ther 2006; 79: P67–P67 (doi:10.1016/j.clpt.2005.1012.1242).
Kim KA, Park PW, Lee OJ, Choi SH, Min BH, Shin KH, Chun BG, Shin JG, Park JY . Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80: 646–656.
Lieb W, Bolbrinker J, Doring A, Hense HW, Erdmann J, Schunkert H, Kreutz R . No association of the CYP3A5*1 allele with blood pressure and left ventricular mass and geometry: the KORA/MONICA Augsburg echocardiographic substudy. Clin Sci (Lond) 2006; 111: 365–372.
Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Philips S, Hilligoss J, Hall SD . Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007; 82: 579–585.
Zhang L, Miyaki K, Wang W, Muramatsu M . CYP3A5 polymorphism and sensitivity of blood pressure to dietary salt in Japanese men. J Hum Hypertens 2010; 24: 345–350.
Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR . Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5: 243–272.
Litchfield WR, Hunt SC, Jeunemaitre X, Fisher ND, Hopkins PN, Williams RR, Corvol P, Williams GH . Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension. Hypertension 1998; 31: 569–574.
Morris DJ, Latif SA, Rokaw MD, Watlington CO, Johnson JP . A second enzyme protecting mineralocorticoid receptors from glucocorticoid occupancy. Am J Physiol 1998; 274: C1245–C1252.
Acknowledgements
This work was supported by the China Postdoctoral Science Foundation (no. 20100481252) and Independent Innovation Foundation of Shandong University (IIFSDU), the Beijing Health System Leading Talent Grant (2009-1-08) and the Beijing Key Science and Technology Program (D111100000611002).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Xi, B., Wang, C., Liu, L. et al. Association of the CYP3A5 polymorphism (6986G>A) with blood pressure and hypertension. Hypertens Res 34, 1216–1220 (2011). https://doi.org/10.1038/hr.2011.112
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/hr.2011.112
Keywords
This article is cited by
-
Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Scientific Reports (2021)
-
CYP3A5 as a candidate gene for hypertension: no support from an unselected indigenous West African population
Journal of Human Hypertension (2016)
-
CYP3A5 polymorphism, amlodipine and hypertension
Journal of Human Hypertension (2014)